BTX 1405
Alternative Names: BTX-1405; BTX-1406Latest Information Update: 01 Apr 2021
At a glance
- Originator BioTheryX
- Class Antineoplastics; Small molecules
- Mechanism of Action KRAS protein modulators; Proteolysis
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 18 Mar 2021 Discontinued for Cancer in USA (unspecified route) (BiotheryX pipeline, March 2021)
- 02 May 2020 Early research in Cancer in USA (unspecified route) (BiotheryX pipeline, May 2020)